Diabetic Foot Ulcer. Type 2 diabetes mellitus with neurological complications
Conditions
Interventions
Intervention 1: Intervention group: Dermaheal Ointment In the form of ready-to-use tubes without printing. The wound and surrounding tissues will
Sponsors
Darudarman Salafchegan Co. (Knowledge-based)
Eligibility
Sex/Gender
All
Age
18 Years to 80 Years
Inclusion criteria
Inclusion criteria: Wagner G 1&2 Diabetic Foot Ulcer Neuropathic and Neuroischemin Ulcer 0.7 = ABI = 1.2
Exclusion criteria
Exclusion criteria: Patient Disagreement to Participate Use of Medications that can Interfere with Wound Healing such as Corticosteroids, Immunosuppressive agents, and Cytotoxic agents
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Ulcer Area. Timepoint: End of every week. Method of measurement: Images & and ruler.;Wound Discharge. Timepoint: End of every week. Method of measurement: Color, odor and amount by wound healing checklist.;Surrounding tissues. Timepoint: End of every week. Method of measurement: Color, hotness, edema and sense by wound healing checklist. | — |
Secondary
| Measure | Time frame |
|---|---|
| ABI. Timepoint: End of treatment. Method of measurement: ABI measurement Device.;FBS. Timepoint: End of treatment. Method of measurement: Glucometer.;Pain severity. Timepoint: End of every week. Method of measurement: Visual pain scale. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactMohammad Reza Amini
Endocrinology and Metabolism Research Institute
Outcome results
None listed